Afficher la notice abrégée

dc.contributor.editorFranco Leal, Raquel
dc.contributor.editorTorriani, Tristan
dc.date.accessioned2021-04-20T16:10:46Z
dc.date.available2021-04-20T16:10:46Z
dc.date.issued2020
dc.identifierONIX_20210420_9781838802646_2696
dc.identifier.urihttps://directory.doabooks.org/handle/20.500.12854/67337
dc.description.abstractThe treatment of inflammatory bowel disease (IBD) has posed a major challenge since its appearance. Biomedical researchers, physicians, gastroenterologists, and surgeons have struggled to improve the quality of life of their patients and have sought, above all else, to keep the disease under remission for as long as possible. Blockers for tumoral necrosis factor alpha (TNF-α) were the first biological drugs to be discovered and for this reason they played a crucial role in the subsequent evolution of IBD treatment. The aim of this book is to provide an overview of such drugs and the latest developments in IBD immunopathology. Our contributors discuss the main indications, efficacy, and possible side effects of the different types of drugs available today for IBD treatment.
dc.languageEnglish
dc.subject.classificationthema EDItEUR::M Medicine and Nursing::MJ Clinical and internal medicine::MJG Endocrinologyen_US
dc.subject.otherGastroenterology
dc.titleBiological Therapy for Inflammatory Bowel Disease
dc.typebook
oapen.identifier.doi10.5772/intechopen.83074
oapen.relation.isPublishedBy78a36484-2c0c-47cb-ad67-2b9f5cd4a8f6
oapen.relation.isbn9781838802646
oapen.relation.isbn9781838802639
oapen.relation.isbn9781789859546
oapen.imprintIntechOpen
oapen.pages140


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée

https://creativecommons.org/licenses/by/3.0/
Excepté là où spécifié autrement, la license de ce document est décrite en tant que https://creativecommons.org/licenses/by/3.0/